Second breakthrough technological advance

VANCOUVER, BC / ACCESSWIRE / September 2, 2022 / Core One Labs Inc. (CSE:COLD), (OTCQB:CLBF), (Frankfurt:LD6)(WKN:A3CSSU) (the “company” or “core one“) is pleased to announce that scientists of its wholly owned subsidiary Awakened Biosciences Inc. (“awakened“) have pioneered the first step in the production of API N,N-dimethyltryptamine (DMT), with the synthesis of a DMT precursor (the “precursor“).

Awakened’s chief researcher, Dr. Tony Durst, has produced and anticipates about 25 grams (g) of precursor demonstrated that the 25 g sample can be successfully converted into a high yield DMT-API product, resulting in approximately 15 g of a contamination-free final DMT-API product. This is Core One’s second breakthrough technological advancement, thanks to the brilliant minds of Awakened. Their efficiency in producing viable psychedelic API compounds will bolster the Company’s position as pioneers in the psychedelics space.

“Core One Labs is now not only able to produce API-grade psilocybin, but has also made a significant breakthrough in the production of cost-effective, API-grade DMT. This is what we have been working on for quite some time with our team of scientists at Awakened, and the success of this process brings Core One Labs and its subsidiaries one step closer to becoming a major manufacturer and supplier of psychedelic drugs in the industry, with the Aiming to be the premier supplier of API-grade psychedelic input materials to drug manufacturing companies,” stated Joel Shacker, CEO of Core One Labs.

With scientific evidence demonstrating and supporting the medical benefits of DMT as both a fast-acting and long-acting antidepressant, numerous biotechnology and pharmaceutical companies have turned their attention to promoting the research and development of effective DMT-based therapies and the production of API-grade DMT. ..